Table 1.
Baseline characteristics.
| Characteristics | LenHAP (n=108) | BevHAP (n=108) | p |
|---|---|---|---|
| Age | 0.20 | ||
| ≤50 | 44 (40.7%) | 35 (32.4%) | |
| >50 | 64 (59.3%) | 73 (67.6%) | |
| Sex | 0.25 | ||
| male | 100 (92.6%) | 95 (88.0%) | |
| female | 8 (7.4%) | 13 (12.0%) | |
| HBsAg | 0.14 | ||
| Positive | 92 (85.2%) | 99 (91.7%) | |
| Negative | 16 (14.8%) | 9 (8.3%) | |
| ECOG PS | 1.0 | ||
| 0 | 104 (96.3%) | 104 (96.3%) | |
| 1 | 4 (3.7%) | 4 (3.7%) | |
| Child-Pugh grade | 0.28 | ||
| A | 106 (98.1%) | 102 (94.4%) | |
| B | 2 (1.9%) | 6 (5.6%) | |
| ALBI grade | 0.68 | ||
| 1 | 67 (62.0%) | 64 (59.3%) | |
| 2 | 40 (37.0%) | 44 (40.7%) | |
| 3 | 1 (0.9%) | 0 (0%) | |
| ALB, median (IQR), g/dL | 41.7 (38.4-43.7) | 41.9 (37.9-44.9) | 0.66 |
| ALT, median (IQR), U/L | 45.0 (30.4-63.8) | 45.7 (29.9-64.2) | 0.78 |
| AST, median (IQR), U/L | 65.1 (40.9-105.0) | 63.7 (38.1-104.9) | 0.85 |
| TBIL, median (IQR), µmol/L | 16.1 (12.5-22.0) | 15.7 (11.8-24.5) | 0.91 |
| PT, median (IQR), s | 12.2 (11.7-12.9) | 12.2 (11.3-12.7) | 0.26 |
| Tumor size, cm, mean (SD) | 11.0 (3.9) | 10.2 (5.0) | 0.094 |
| ≤10 | 50 (46.3%) | 61 (56.5%) | 0.13 |
| >10 | 58 (53.7%) | 47 (43.5%) | |
| Tumor number | 0.48 | ||
| ≤3 | 35 (32.4%) | 40 (37.0%) | |
| >3 | 73 (67.6%) | 68 (63.0%) | |
| PVTT (Japan) | |||
| Vp0 | 43 (39.8%) | 45 (41.7%) | 0.89 |
| Vp1-2 | 15 (13.9%) | 12 (11.1%) | |
| Vp3 | 21 (19.4%) | 24 (22.2%) | |
| Vp4 | 29 (26.9%) | 27 (25.0%) | |
| HVTT | 0.33 | ||
| No | 93 (86.1%) | 93 (86.1%) | |
| Hepatic vein | 7 (6.5%) | 11 (10.2%) | |
| Inferior vena cava | 8 (7.4%) | 4 (3.7%) | |
| Extrahepatic metastasis | 0.56 | ||
| No | 76 (70.4%) | 72 (66.7%) | |
| Yes | 32 (29.6%) | 36 (33.3%) | |
| AFP, ng/ml, median (IQR) | 1097 (40.3-25969) | 550 (21.1-11523) | 0.36 |
| ≤400 | 48 (44.4%) | 52 (48.1%) | 0.59 |
| >400 | 60 (55.6%) | 56 (51.9%) | |
| BCLC stage | 0.43 | ||
| A or B | 29 (26.9%) | 24 (22.2%) | |
| C | 79 (73.1%) | 84 (77.8%) | |
| Potentially resectable* | 0.77 | ||
| No | 70 (64.8%) | 72 (66.7%) | |
| Yes | 38 (35.2%) | 36 (33.3%) | |
| PD-1/L1 antibody | p<0.001 | ||
| PD-1 antibody | |||
| Tislelizumab | 3 (2.8%) | 1 (0.9%) | |
| Camrelizumab | 10 (9.3%) | 0 | |
| Pembrolizumab | 5 (4.6%) | 0 | |
| Toripalimab | 28 (25.9%) | 0 | |
| Sintilimab | 61 (56.5%) | 55 (50.9%) | |
| PD-L1 antibody | |||
| Atezolizumab | 1 (0.9%) | 52 (48.1%) | |
*Potentially resectable were defined as that the tumors were localized in the same segment or half of liver (or the lesions outside the resection area could be treated by ablation at the same time) and were consistent with resectable hepatic vein invasion, portal vein invasion (PVTT) (except main PVTT) or bile duct tumor thrombus without distant metastasis.